ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Small Cell Lung: Extensive Disease – First LineChemotherapy:Platinol (Cisplatin) VP-16 (Etoposide) EP=High; FN=10%-20%Cisplatin 75-80mg/m 2 D1Etoposide 80-100mg/m 2 D1-3ORCisplatin 25mg/m 2 D1-3Etoposide 100mg/m 2 D1-3q 21 Day Cycle>> J Clin Oncol 20 :4665-4672, 2002>> J Clin Oncol 12 :2022-2034, 1994>> J Clin Oncol 3:1471-1477, 1985Paraplatin (Carboplatin) VP-16 (Etoposide) EP=Moderate; FN=10%-20%Carboplatin AUC 5-6 D1Etoposide 100mg/m 2 D1-3q 21 Day Cycle>> J Clin Oncol 17:3540-3545, 1999Platinol (Cisplatin) Camptosar (Irinotecan) EP=High; FN=10%-20%Cisplatin 60mg/m 2 D1Irinotecan 60mg/m 2 D1, D8, D15q 28 Day CycleORCisplatin 30mg/m 2 D1, D8Irinotecan 65mg/m 2 D1, D8q 21 Day Cycle>> N Engl J Med 346:85-91, 2002>> J Clin Oncol 24:2038-2043, 2006<strong>Clinical</strong> Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Best Supportive Care and/or Hospice:Consider supportive care options and Hospice when appropriate.Page 31 of 39© 2013 by <strong>ION</strong> <strong>Solutions</strong>. All rights reserved
Change language